“I hope that we help manage more serious diseases that are currently handled only with drugs.”
Since launch in October 2018, Dr. Li has led Filtricine from cell-based technology to clinical trial initiation. He and the cofounders incubated the company at IndieBio and secured seed financing led by True Ventures and SOSV. As an expert in cancer metabolism, Dr. Li discovered and patented Targeted Nutrients Deprivation while at Stanford University Medical School. That patent was followed by two additional Filtricine patents. Dr. Li holds a PhD from the University of Maryland and trained with Dr. Mike Snyder at Yale and Stanford Universities.